Cambridge MedTech Firm CMR Surgical Eyes £3.1 Billion Sale in Strategic Shake-Up.

British medical robotics firm CMR Surgical is exploring a potential sale worth up to $4 billion (£3.1 billion), as the Cambridge-based company prepares to expand into the lucrative U.S. healthcare market, the Financial Times reported. The company, known for its Versius surgical robot, has reportedly engaged advisers to oversee the process, which could attract interest from global medical giants.

Founded in 2014, CMR Surgical has established itself as a key player in the UK’s burgeoning life sciences sector, with its robotic system already used in over 30 countries and more than 30,000 procedures. The news of a possible sale comes just months after the company secured FDA approval for Versius in gallbladder surgery—a major gateway to the U.S. market. CMR recently raised $200 million in funding, valuing the business at around $3 billion, with backing from global investors including SoftBank and GE HealthCare.

The prospective sale underscores both investor appetite for surgical robotics and the UK’s ambition to retain homegrown innovation within its borders. As Britain looks to strengthen its position as a global hub for medical technology, CMR’s next steps will be closely watched in Westminster and on trading floors alike. While a deal is not certain, any transaction would mark one of the largest medtech exits in recent British history.